S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
OTCMKTS:ACUR

Acura Pharmaceuticals Stock Forecast, Price & News

$0.48
0.00 (0.00%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.45
$0.48
50-Day Range
$0.48
$0.59
52-Week Range
$0.19
$0.75
Volume
1,126 shs
Average Volume
6,180 shs
Market Capitalization
$31.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.59
30 days | 90 days | 365 days | Advanced Chart
Receive ACUR News and Ratings via Email

Sign-up to receive the latest news and ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Acura Pharmaceuticals logo

About Acura Pharmaceuticals

Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. Its technology platforms include AVERSION, IMPEDE, and LIMITX. The company was founded on April 10, 1935 and is headquartered in Palatine, IL.

Headlines

Acura Pharmaceuticals (ACUR) vs. Its Peers Critical Survey
January 8, 2022 |  americanbankingnews.com
Financial Survey: Acura Pharmaceuticals (ACUR) vs. Its Competitors
December 29, 2021 |  americanbankingnews.com
Vuzix in Distribution Deal with Acuraflow
October 1, 2021 |  marketwatch.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
OTCMKTS:ACUR
Previous Symbol
NASDAQ:ACUR
CUSIP
00509L70
Employees
13
Year Founded
N/A

Sales & Book Value

Annual Sales
$3.57 million
Book Value
($0.27) per share

Profitability

Net Income
$-1.21 million
Pretax Margin
-51.27%

Debt

Price-To-Earnings

Miscellaneous

Free Float
52,075,000
Market Cap
$31.32 million
Optionable
Not Optionable

Company Calendar

Last Earnings
2/28/2020
Today
1/23/2022
Next Earnings (Estimated)
3/29/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.29 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Acura Pharmaceuticals (OTCMKTS:ACUR) Frequently Asked Questions

How has Acura Pharmaceuticals' stock price been impacted by COVID-19?

Acura Pharmaceuticals' stock was trading at $0.34 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACUR shares have increased by 41.2% and is now trading at $0.48.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Acura Pharmaceuticals?

Acura Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 22,600 shares, an increase of 117.3% from the December 15th total of 10,400 shares. Based on an average trading volume of 23,800 shares, the days-to-cover ratio is presently 0.9 days.
View Acura Pharmaceuticals' Short Interest
.

When is Acura Pharmaceuticals' next earnings date?

Acura Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Acura Pharmaceuticals
.

How were Acura Pharmaceuticals' earnings last quarter?

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) released its earnings results on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $1.32 million for the quarter.
View Acura Pharmaceuticals' earnings history
.

Who are Acura Pharmaceuticals' key executives?

Acura Pharmaceuticals' management team includes the following people:
  • Robert B. Jones, President, Chief Executive Officer & Director
  • Peter A. Clemens, Chief Financial Officer, Secretary & Senior VP
  • Bob Seiser, Treasurer, Vice President & Controller
  • Albert W. Brzeczko, Vice President-Pharmaceutical Sciences

What other stocks do shareholders of Acura Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acura Pharmaceuticals investors own include Denali Therapeutics (DNLI), Adamis Pharmaceuticals (ADMP), Ekso Bionics (EKSO), VIVUS (VVUS), Fulcrum Therapeutics (FULC), (GBSN) (GBSN), Trevena (TRVN), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA) and Advanced Micro Devices (AMD).

What is Acura Pharmaceuticals' stock symbol?

Acura Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ACUR."

How do I buy shares of Acura Pharmaceuticals?

Shares of ACUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acura Pharmaceuticals' stock price today?

One share of ACUR stock can currently be purchased for approximately $0.48.

How much money does Acura Pharmaceuticals make?

Acura Pharmaceuticals has a market capitalization of $31.32 million and generates $3.57 million in revenue each year. The specialty pharmaceutical company earns $-1.21 million in net income (profit) each year or ($0.03) on an earnings per share basis.

How many employees does Acura Pharmaceuticals have?

Acura Pharmaceuticals employs 13 workers across the globe.

What is Acura Pharmaceuticals' official website?

The official website for Acura Pharmaceuticals is www.acurapharm.com.

Where are Acura Pharmaceuticals' headquarters?

Acura Pharmaceuticals is headquartered at 616 N. NORTH COURT SUITE 120, PALATINE IL, 60067.

How can I contact Acura Pharmaceuticals?

Acura Pharmaceuticals' mailing address is 616 N. NORTH COURT SUITE 120, PALATINE IL, 60067. The specialty pharmaceutical company can be reached via phone at (847) 705-7709, via email at [email protected], or via fax at 847-705-5399.


This page was last updated on 1/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.